Needham Maintains a Buy on Autolus Therapeutics (AUTL), Sets a $10 PT

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best biotech penny stocks to buy right now. On July 21, analyst Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) with a $10.00 price target.

A laboratory technician carefully studying a microscope with a biopharmaceutical product inside.

The analyst told investors that the conditional EU approval of Aucatzyl (obe-cel) for adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is a notable milestone for Autolus Therapeutics plc (NASDAQ:AUTL), adding that Aucatzyl has already attained conditional approval in the UK and a launch is expected soon.

Blum further reasoned that the US market is showing early demand, corroborated by $9 million in sales for fiscal Q1 2025. When considered in conjunction with the estimated sales growth, these factors support the optimistic rating for Autolus Therapeutics plc (NASDAQ:AUTL).

Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer and focuses on chimeric antigen receptor (CAR) T cell therapy.

The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.